Cytek Biosciences CTKB
Valuation
Multiples measured against the stock's own five-year history
Above its usual level · 70th percentile, 5-year average -141.1x
Around its usual level · 58th percentile, 5-year average 2.5x
#3390 of 5328 stocks by PB (1 = cheapest)
Around its usual level · 42nd percentile, 5-year average 6.3x
#3529 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 2.38 | – | 2.54 | 58% (pricier than usual) | #3390 of 5328 (1 = cheapest) |
| PE | -9.27 | -35.44 | -141.15 | 70% (pricier than usual) | – |
| PS | 3.68 | 3.50 | 6.27 | 42% (cheaper than usual) | #3529 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on CTKB.
Sign in to join the discussion.